ProMetic Life Sciences (TSE:PLI) had its price objective trimmed by National Bank Financial from C$1.00 to C$0.75 in a research note published on Wednesday morning. The firm currently has an underperform rating on the stock.
Several other brokerages have also issued reports on PLI. Canaccord Genuity decreased their price target on shares of ProMetic Life Sciences from C$4.00 to C$2.00 in a research note on Tuesday. TD Securities decreased their price target on shares of ProMetic Life Sciences from C$3.50 to C$2.00 in a research note on Monday, April 2nd. CIBC decreased their price target on shares of ProMetic Life Sciences from C$2.15 to C$0.60 in a research note on Monday, April 2nd. Finally, Royal Bank of Canada decreased their price target on shares of ProMetic Life Sciences from C$3.50 to C$2.00 and set an outperform rating for the company in a research note on Monday, April 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of C$1.89.
Shares of TSE PLI opened at C$0.85 on Wednesday. ProMetic Life Sciences has a 12 month low of C$0.63 and a 12 month high of C$2.24.
ILLEGAL ACTIVITY WARNING: This report was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3336771/prometic-life-sciences-pli-price-target-cut-to-c0-75.html.
About ProMetic Life Sciences
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.